Universität zu Köln

Buehler, A., Wendtner, C-M, Kipps, T. J., Rassenti, L., Fraser, G. A. M., Michallet, A-S, Hillmen, P., Duerig, J., Gregory, S. A., Kalaycio, M., Aurran-Schleinitz, T., Trentin, L., Gribben, J. G., Chanan-Khan, A., Purse, B., Zhang, J., De Bedout, S., Mei, J., Hallek, M. and Stilgenbauer, S. (2016). Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J., 6. LONDON: NATURE PUBLISHING GROUP. ISSN 2044-5385

Full text not available from this repository.

Abstract

Efficacy of lenalidomide was investigated in 103 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated on the prospective, multicenter randomized phase-II CLL-009 trial. Interphase cytogenetic and mutational analyses identified TP53 mutations, unmutated IGHV, or del(17p) in 36/96 (37.5%), 68/88 (77.3%) or 22/92 (23.9%) patients. The overall response rate (ORR) was 40.4% (42/104). ORRs were similar irrespective of TP53 mutation (36.1% (13/36) vs 43.3% (26/60) for patients with vs without mutation) or IGHV mutation status (45.0% (9/20) vs 39.1% (27/68)); however, patients with del(17p) had lower ORRs than those without del(17p) (21.7% (5/22) vs 47.1% (33/70); P = 0.049). No significant differences in progression-free survival and overall survival (OS) were observed when comparing subgroups defined by the presence or absence of high-risk genetic characteristics. In multivariate analyses, only multiple prior therapies (>= 3 lines) significantly impacted outcomes (median OS: 21.2 months vs not reached; P = 0.019). This analysis indicates that lenalidomide is active in patients with relapsed/refractory CLL with unfavorable genetic profiles, including TP53 inactivation or unmutated IGHV.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Buehler, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wendtner, C-M UNSPECIFIED UNSPECIFIED UNSPECIFIED Kipps, T. J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rassenti, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Fraser, G. A. M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Michallet, A-S UNSPECIFIED UNSPECIFIED UNSPECIFIED Hillmen, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Duerig, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gregory, S. A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kalaycio, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Aurran-Schleinitz, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Trentin, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gribben, J. G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Chanan-Khan, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Purse, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Zhang, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED De Bedout, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mei, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Stilgenbauer, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-282446
DOI:	10.1038/bcj.2016.9
Journal or Publication Title:	Blood Cancer J.
Volume:	6
Date:	2016
Publisher:	NATURE PUBLISHING GROUP
Place of Publication:	LONDON
ISSN:	2044-5385
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SURVIVAL; EFFICACY; CLL Multiple languages Oncology; Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/28244